Hammouda, Hossam Hammouda Nada

Publications

Sort by

Co-Author Network

selected publications

Overcoming the undruggable barrier: Structure-guided discovery of a potent small molecule CD28 antagonist with translational potential. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025 Academic Article GET IT
Restoring Amyloid Clearance via Astrocytes: Z17 Is a Selective Inhibitor of CHI3L1 in Alzheimers Disease. 2025 GET IT
Using biophysical techniques to enhance Early-Stage Drug discovery: the impact and challenges. Expert opinion on drug discovery. 2025 Editorial Article GET IT
As48, a first-in-class dual-function TREM2 modulator: Receptor activation and shedding inhibition. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025 Academic Article GET IT
HTS-Oracle: Experimentally validated AI-enabled prioritization for generalizable small molecule hit discovery. 2025 GET IT
High-Throughput Fragment Screening Identifies a New Small Molecule Scaffold that Modulates TREM2 Signaling. 2025 GET IT
An Integrated Biophysical Fragment Screening Approach Identifies Novel Binders of the CD28 Immune Receptor. 2025 GET IT
Discovery of CD28-Targeted Small Molecule Inhibitors of T Cell Co-Stimulation Using Affinity Selection-Mass Spectrometry (AS-MS) and Ex Vivo Validation. Journal of medicinal chemistry. 2025 Academic Article GET IT
TREM2 activation by first-in-class direct small molecule agonists: DEL screening, optimization, biophysical validation, and functional characterization. European journal of medicinal chemistry. 2025 Academic Article GET IT
Identification of a First-In-Class Small Molecule CAPON Binder Using Affinity Selection-Mass Spectrometry Screening. 2025 GET IT
Targeting CAPON to modulate the CAPON-NOS Axis: a computational approach. Computational and structural biotechnology journal. 2025 Academic Article GET IT
Discovery of small molecule CHI3L1 inhibitors by SPR-based high-throughput screening. Bioorganic & medicinal chemistry letters. 2025 Academic Article GET IT
Surface Plasmon Resonance (SPR)-Based Workflow for High-Throughput Discovery of CD28-Targeted Small Molecules. ACS omega. 2025 Academic Article GET IT
Discovery of a CHI3L1-Targeted Small Molecule Modulating Neuroinflammation in Alzheimer's Disease via DNA-Encoded Library (DEL) Screening ^†. 2025 GET IT
Affinity Selection-Mass spectrometry coupled with biophysical validation enables proof-of-concept discovery of CHI3L1 binders. Biochemical and biophysical research communications. 2025 Academic Article GET IT
Affinity Selection-Mass Spectrometry Coupled with Biophysical Validation Enables Proof-of-Concept Discovery of CHI3L1 Binders. 2025 GET IT
Structure-Guided Optimization and Functional Characterization of Small Molecule Antagonists Targeting CD28 Costimulation. 2025 GET IT
Design and validation of the first-in-class PROTACs for targeted degradation of the immune checkpoint LAG-3. Bioorganic & medicinal chemistry letters. 2025 Academic Article GET IT
c-KIT Small Molecule Inhibitors as a Therapeutic Strategy for Melanoma: Clinical Insights, SAR, and Future Directions. Archiv der Pharmazie. 2025 Review GET IT
Discovery of a first-in-class SLIT2 binder disrupting the SLIT2/ROBO1 axis via DNA-encoded library (DEL) screening. RSC medicinal chemistry. 2025 Academic Article GET IT
Discovery and validation of LAGi-DEL: A nanomolar LAG-3 inhibitor that reverses immune suppression in tumor-immune co-culture models. European journal of medicinal chemistry. 2025 Academic Article GET IT
LMT2368 (1-(4-Chlorophenyl)-3-(3-fluoro-5-(trifluoromethyl)phenyl)urea) Negatively Regulates Inflammation by Inhibiting NLRP3 Inflammasome Activation. Pharmaceutics. 2025 Academic Article GET IT
As48, a First-in-Class Dual-Function TREM2 Modulator: Receptor Activation and Shedding Inhibition. 2025 GET IT
Phenotypic and targeted drug discovery in immune therapeutics: challenges, opportunities, and future directions. RSC advances. 2025 Review GET IT
Discovery and Optimization of LAG-3-Targeted Small Molecules via DNA-Encoded Chemical Library (DEL) Screening for Cancer Immunotherapy. Journal of medicinal chemistry. 2025 Academic Article GET IT
Targeting the CAPON-NOS Axis: A Computational Strategy for Small Molecule Modulator Discovery. 2025 GET IT
Discovery of CD28-Targeted Small Molecule Inhibitors of T Cell Co-stimulation Using Affinity Selection-Mass Spectrometry (AS-MS) and Ex Vivo Validation. 2025 GET IT
Discovery of a Small Molecule TREM2 Agonist with Improved In Vitro Pharmacokinetic Profile and Validated Target Engagement. ACS medicinal chemistry letters. 2025 Academic Article GET IT
HTS-Oracle: A Retrainable AI Platform for High-Confidence Hit Identification Across Difficult-to-Drug Targets. 2025 GET IT
CHI3L1-targeted small molecules as glioblastoma therapies: Virtual screening-based discovery, biophysical validation, pharmacokinetic profiling, and evaluation in glioblastoma spheroids. European journal of medicinal chemistry. 2025 Academic Article GET IT
Lead optimization of a CHI3L1 inhibitor for Glioblastoma: Enhanced target engagement, pharmacokinetics, and efficacy in 3D spheroid models. European journal of medicinal chemistry. 2025 Academic Article GET IT
Discovery of an Achiral Small Molecule TREM2 Agonist with Improved Pharmacokinetic Profile and Validated Target Engagement. 2025 GET IT
Discovery of a First-in-Class SLIT2 Binder Disrupting the SLIT2/ROBO1 Axis via DNA-Encoded Library (DEL) Screening. 2025 GET IT
Surface Plasmon Resonance (SPR)-Based Workflow for High-Throughput Discovery of CD28-Targeted Small Molecules. 2025 GET IT
TREM2 Activation by First-in-Class Direct Small Molecule Agonists: DEL Screening, Optimization, Biophysical Validation, and Functional Characterization. 2025 GET IT
CHI3L1-Targeted Small Molecules as Glioblastoma Therapies: Virtual Screening-Based Discovery, Biophysical Validation, Pharmacokinetic Profiling, and Evaluation in Glioblastoma Spheroids. 2025 GET IT
First-in-class dual inhibitors of MASTL and Aurora A kinase: Discovery of selective cyclohexa[b]thiophenes with potent anticancer activity. European journal of medicinal chemistry. 2025 Academic Article GET IT
Times cited: 2
Virtual screening: hope, hype, and the fine line in between. Expert opinion on drug discovery. 2025 Review GET IT
Times cited: 7
Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets. Pharmaceuticals (Basel, Switzerland). 2024 Review GET IT
Times cited: 8
New insights into protein-protein interaction modulators in drug discovery and therapeutic advance. Signal transduction and targeted therapy. 2024 Review GET IT
Times cited: 69
Chemical induction of the interaction between AIMP2-DX2 and Siah1 to enhance ubiquitination. Cell chemical biology. 2024 Academic Article GET IT
Times cited: 1
Chalcone-based benzenesulfonamides as potent and selective inhibitors for human carbonic anhydrase II: Design, synthesis, in vitro, and in silico studies. Archiv der Pharmazie. 2024 Academic Article GET IT
Times cited: 1
From pixels to druggable leads: A CADD strategy for the design and synthesis of potent DDR1 inhibitors. Computer methods and programs in biomedicine. 2024 Academic Article GET IT
Times cited: 7
A novel indole derivative, 2-{3-[1-(benzylsulfonyl)piperidin-4-yl]-2-methyl-1H-indol-1-yl}-1-(pyrrolidin-1-yl)ethenone, suppresses hedgehog signaling and drug-resistant tumor growth. Archiv der Pharmazie. 2024 Academic Article GET IT
Times cited: 2
PT-Finder: A multi-modal neural network approach to target identification. Computers in biology and medicine. 2024 Academic Article GET IT
Times cited: 3
Natural products as IL-6 inhibitors for inflammatory diseases: Synthetic and SAR perspective. Medicinal research reviews. 2024 Review GET IT
Times cited: 15
Machine Learning-Based Approach to Developing Potent EGFR Inhibitors for Breast Cancer-Design, Synthesis, and In Vitro Evaluation. ACS omega. 2023 Academic Article GET IT
Times cited: 14
Cantharidin-Based Verbenone Derivatives as a Novel Insecticide against Plutella xylostella: Design, Synthesis, Insecticidal Activity Evaluation, and 3D QSAR Study. Biomolecules. 2023 Academic Article GET IT
Times cited: 4
Integration of Hybridization Strategies in Pyridine-Urea Scaffolds for Novel Anticancer Agents: Design, Synthesis, and Mechanistic Insights. Molecules (Basel, Switzerland). 2023 Academic Article GET IT
Times cited: 6
Identification of Potent hDHODH Inhibitors for Lung Cancer via Virtual Screening of a Rationally Designed Small Combinatorial Library. ACS omega. 2023 Academic Article GET IT
Times cited: 6
Small Molecule c-KIT Inhibitors for the Treatment of Gastrointestinal Stromal Tumors: A Review on Synthesis, Design Strategies, and Structure-Activity Relationship (SAR). International journal of molecular sciences. 2023 Review GET IT
Times cited: 8
Design, Synthesis and Biological Evaluation of Novel MDH Inhibitors Targeting Tumor Microenvironment. Pharmaceuticals (Basel, Switzerland). 2023 Academic Article GET IT
Times cited: 8
Perspective for Discovery of Small Molecule IL-6 Inhibitors through Study of Structure-Activity Relationships and Molecular Docking. Journal of medicinal chemistry. 2023 Review GET IT
Times cited: 32
Discovery and optimization of natural-based nanomolar c-Kit inhibitors via in silico and in vitro studies. Journal of biomolecular structure & dynamics. 2023 Academic Article GET IT
Times cited: 9
4-Anilinoquinazoline-based benzenesulfonamides as nanomolar inhibitors of carbonic anhydrase isoforms I, II, IX, and XII: design, synthesis, in-vitro, and in-silico biological studies. Journal of enzyme inhibition and medicinal chemistry. 2022 Academic Article GET IT
Times cited: 17
Identification of 1H-purine-2,6-dione derivative as a potential SARS-CoV-2 main protease inhibitor: molecular docking, dynamic simulations, and energy calculations. PeerJ. 2022 Academic Article GET IT
Times cited: 31
Novel cudraisoflavone J derivatives as potent neuroprotective agents for the treatment of Parkinson's disease via the activation of Nrf2/HO-1 signaling. European journal of medicinal chemistry. 2022 Academic Article GET IT
Times cited: 6
Identification of Novel and Potent Indole-Based Benzenesulfonamides as Selective Human Carbonic Anhydrase II Inhibitors: Design, Synthesis, In Vitro, and In Silico Studies. International journal of molecular sciences. 2022 Academic Article GET IT
Times cited: 16
Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches. Computers in biology and medicine. 2022 Academic Article GET IT
Times cited: 63
Hit Identification of a Novel Quinazoline Sulfonamide as a Promising EphB3 Inhibitor: Design, Virtual Combinatorial Library, Synthesis, Biological Evaluation, and Docking Simulation Studies. Pharmaceuticals (Basel, Switzerland). 2021 Academic Article GET IT
Times cited: 10
Melatonin Analogues Potently Inhibit MAO-B and Protect PC12 Cells against Oxidative Stress. Antioxidants (Basel, Switzerland). 2021 Academic Article GET IT
Times cited: 28
Development of New Meridianin/Leucettine-Derived Hybrid Small Molecules as Nanomolar Multi-Kinase Inhibitors with Antitumor Activity. Biomedicines. 2021 Academic Article GET IT
Times cited: 11
The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer. International journal of molecular sciences. 2021 Review GET IT
Times cited: 72
Structure Activity Relationship of Key Heterocyclic Anti-Angiogenic Leads of Promising Potential in the Fight against Cancer. Molecules (Basel, Switzerland). 2021 Review GET IT
Times cited: 18
Inhibition studies on a panel of human carbonic anhydrases with N1-substituted secondary sulfonamides incorporating thiazolinone or imidazolone-indole tails. Journal of enzyme inhibition and medicinal chemistry. 2018 Academic Article GET IT
Times cited: 46

more ...

less ...

Background

education and training

Ph.D., Dongguk University (South Korea) 23
M.S., Cairo University (Egypt) 2018
B.S., Cairo University (Egypt) 2012

Contact

full name

Hossam Hammouda Nada Hammouda

primary email

hoh4004@med.cornell.edu

VIVO Weill Cornell Medical College

Hossam Hammouda Nada Hammouda Postdoctoral Associate in Radiology

Publications

selected publications

Background

education and training

Contact

full name

primary email